v3.26.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
ASSETS    
Cash and cash equivalents $ 10,443 $ 15,956
Prepaid and other current assets 570 1,747
Total current assets 11,013 17,703
Property and equipment, net 14 18
Other assets 0 23
Total assets 11,027 17,744
Liabilities    
Accounts payable 836 1,019
Accrued liabilities 2,151 2,052
Total current liabilities 2,987 3,071
Other long-term liabilities 50 72
Total liabilities 3,037 3,143
Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 9,119,742 and 8,834,613 shares at June 30, 2026 and December 31, 2025, respectively; and outstanding, 9,119,004 and 8,833,875 shares at June 30, 2026 and December 31, 2025, respectively 9 9
Additional paid-in capital 581,030 580,243
Treasury stock, at cost; 738 shares at June 30, 2026 and December 31, 2025 (708) (708)
Accumulated deficit (572,070) (564,652)
Accumulated other comprehensive loss (17) (37)
Total Lisata Therapeutics, Inc. stockholders' equity 8,244 14,855
Non-controlling interests (254) (254)
Total equity 7,990 14,601
Total liabilities, non-controlling interests and stockholders' equity $ 11,027 $ 17,744